January 9, 2019
Thank you to all who voted for the recent IDSA governance changes and expressed their passion for increasing inclusion, diversity, access and equity in the Society’s governance.Read More
Advocacy for robust federal funding to support domestic and global ID/HIV research and public health activities remains a critical priority for IDSA and HIVMA.Read More
In this feature, a panel of IDSA members identifies and critiques important new studies in the current literature that have a significant impact on the practice of infectious diseases medicine.
Reviews in this issue: Perinatal Hepatitis C Virus Exposure: An Increasing Public Health Concern; Ibalizumab: A New Medicine, with a New Mechanism, to Treat HIV
As part of the “six protected classes” of drugs under Medicare Part D, antiretrovirals have been exempted from prior authorization or other utilization management techniques.Read More
If you plan to take the Traditional MOC Exam or the Knowledge Check-in in 2019, registration is now open.Read More
IDSA’s Science Speaks blog discussed the WHO releasing updated drug-resistant TB guidelines and stalled funding for infectious disease responses.Read More